This white paper examines obesity in Türkiye as a growing chronic disease, public health challenge, and economic burden. More than one-third of adults currently live with obesity, and over half could be affected by 2035. Although Türkiye has expanded screening, awareness programs, and Healthy Life Centers, many patients still enter care late, often after developing related conditions. Lifestyle changes remain central to treatment, while GLP-1 medicines are rapidly reshaping clinical practice and patient demand. Key barriers include affordability, limited follow-up support, fragmented care, and treatment discontinuation. The paper also highlights pharmacists’ growing role and predicts that oral therapies and semaglutide’s loss of exclusivity could improve access, affordability, and long-ter

Join for free to read